Status:
COMPLETED
Comorbidities And Reducing inEquitieS
Lead Sponsor:
Medstar Health Research Institute
Collaborating Sponsors:
Pfizer
American Cancer Society, Inc.
Conditions:
Cancer, Breast
Diabetes Mellitus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Black cancer patients tend to have worse outcomes than White cancer patients. Some of this disparity may be due to comorbidities. The purpose of this study is to improve management of co-morbidities a...
Eligibility Criteria
Inclusion
- Black women with a diagnosis of stage 0-IV breast cancer and within a month of treatment initiation or with 6+ months of treatment left OR Black men with a history of prostate cancer who are on long-term androgen deprivation therapy;
- Blood pressure \>=120/80 OR diagnosis of diabetes
- Individuals who develop these conditions during treatment such as those scheduled to initiate steroid-containing chemotherapy or targeted PI3K inhibitor therapies
- Access to a smartphone and/or internet for the duration of the study.
- Can understand and communicate in English
Exclusion
- \- Unwilling to participate in a 6-month study
Key Trial Info
Start Date :
May 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 10 2023
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT04836221
Start Date
May 5 2021
End Date
June 10 2023
Last Update
June 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States, 20010